Pipeline

NEBULA: Enabling the Undruggable

Physics-driven generative AI that opens a drug-discovery space that no dataset has ever reached.

NEBULA’s dataset-free AI technology discovers every 3-D conformation a therapeutic target can adopt, revealing details that conventional methods cannot access. By unlocking targets that have long been labeled undruggable, we fast-track novel therapies—while competitors are still searching for data.

Contact us !
Pipeline

The Drug Discovery’s 80 % blind spot

Only 20 % of the ~5,000 identified therapeutic protein targets are currently “druggable.”
80 % remain undruggable, blocking innovation and driving late-stage failures, while competition for the small slice grows fiercer.

Harnessing the capabilities of dataset-free Generative AI to tackle undruggable drug targets

Our Technological Stack

NEBULA GenAI Conf

A technology to uncover the conformational landscape of a drug-target in ultra-high atomic resolution. It allows to uncover cryptic or ephemeral binding pockets and novel sites for allosteric modulation. It also reveals the mechanism of the drug target itself, which is crucial for the Market Approval process.

NEBULA GenAI New Molecule

Generate completely unseen, novel drug-like molecules that bind to a drug target.

NEBULA Binding AI

A technology to predict the binding strength of a drug with experimental accuracy. This allows us to know if a drug is potent enough before it is even synthesized.

NEBULA Match AI

A platform to match discovered drugs to existing molecules with a high-speed screen of more than 100,000 molecules per day. This helps find molecules that already exist, are available for purchase, or are on the market (drug repurposing).

NEBULA SCREEN AI

A platform to ensure that the drug-like molecules we produce are screened to be non-toxic, adhere to ADME rules, and are easily synthesizable.

NEBULA’s platform maps dynamic 3-D conformations, generates novel drug-like molecules, predicts binding strength before synthesis, matches candidates to existing compounds for rapid repurposing, and screens for non-toxicity, ADME adherence, and synthesizability, unlocking medicines for diseases long viewed as undruggable.

Pipeline Focus: Cancer and Neurological Disease

We apply NEBULA Enabeling Technology to develop therapies for hard-to-treat cancers (e.g. advanced pancreatic, lung, and blood cancers) and CNS disorders (such as drug-resistant epilepsy and progressive neurodegeneration).

Meet the TEAM

See who is behind the company

Daniel Wiczew

An entrepreneur with deep expertise in artificial intelligence, biomedical sciences, and drug design. Daniel brings unparalleled technical knowledge to NEBULA, driving our technology’s development and application in drug discovery.

Mounir Tarek

A senior research director with extensive experience in molecular modeling and computational biophysics. Mounir leads NEBULA with a vision to transform the pharmaceutical industry through innovative AI technologies.

Fabrice Balavoine

An accomplished biotech executive with over 20 years of leadership in drug discovery and pharmaceutical development. Fabrice drives NEBULA’s commercial growth by securing strategic partnerships and leveraging his proven success.

SPECIAL THANKS TO

Frequently Asked Questions

Q1: How does NEBULA’s technology differ from traditional drug discovery methods?

NEBULA’s AI-driven platform provides a comprehensive mapping of therapeutic target structures, capturing dynamic conformations that traditional methods often miss. This enhances the accuracy of virtual screening and increases the likelihood of identifying effective drug candidates.

Q2: How does NEBULA compare to AlphaFold in protein structure prediction?

While AlphaFold revolutionized protein science by predicting static 3D structures of proteins from amino acid sequences, it primarily provides a single, most probable conformation. Proteins in physiological conditions are dynamic and can adopt multiple conformations. NEBULA goes beyond static predictions by mapping the full spectrum of a protein’s possible shapes. This dynamic profiling offers deeper insights into how drugs can interact with targets in real-world conditions, enhancing the success rate of drug discovery.

Q3: Can NEBULA integrate with our existing drug discovery processes?

Absolutely. Our solutions are designed to complement and enhance your current workflows. We provide detailed target profiling that seamlessly integrates into your virtual screening and drug design processes.

Q4: How can pharmaceutical companies partner with NEBULA?

Pharmaceutical and biotech companies can partner with NEBULA through our flexible, project-based service model. We offer customized solutions tailored to the complexity of your therapeutic targets, including initial setup, milestone deliverables, and revenue-sharing agreements. This collaborative approach aligns our success with yours, fostering a strong partnership for mutual benefit.

Q5: What support does NEBULA provide during a project?

Our team offers comprehensive support, including expert consultation, detailed data analysis, and ongoing collaboration. We’re committed to ensuring optimal outcomes for your drug discovery efforts.

Stay Tuned for the Latest in Drug Target Innovation

Older posts:

Get in Touch

Send us a message!

We’d love to hear from you. Please fill out the contact form below, and we’ll get back to you promptly.

Follow on Social

You agree to receive email communication from us by submitting this form.